Home › Acute Myeloid Leukemia › Michigan › Ann Arbor
Acute Myeloid Leukemia clinical trials in Ann Arbor, MI
17 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Ann Arbor (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi away
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi away
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi away
- and 4 more
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi away
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti · 7 mi away
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi away
- and 1 more
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
RecruitingPhase 1
- C S Mott Children's Hospital, Ann Arbor
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi away
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi away
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi away
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi away
- and 1 more
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- C S Mott Children's Hospital, Ann Arbor
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
RecruitingPhase 3
- C S Mott Children's Hospital, Ann Arbor
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- C S Mott Children's Hospital, Ann Arbor
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- C.S. Mott Children's Hospital, Ann Arbor
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- University of Michigan, Ann Arbor
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- University of Michigan, Ann Arbor
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- University of Michigan, Ann Arbor
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- University of Michigan Comprehensive Cancer Center, Ann Arbor
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA40 studies
- Seattle, WA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA30 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Other studies in Ann Arbor
- Prostate Cancer27 studies
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer26 studies
- Cancer (all types)25 studies
- Colorectal Cancer23 studies
- Lung Cancer23 studies
- Heart Failure22 studies
- Cardiovascular Disease16 studies
- Pancreatic Cancer14 studies
- Melanoma12 studies
- Kidney Cancer (Renal Cell Carcinoma)12 studies
- Head and Neck Squamous Cell Carcinoma12 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.